Navigation Links
Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
Date:4/30/2009

CALGARY, April 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2009 Annual and Special Meeting of the Shareholders will be held on Tuesday, May 5, 2009 at 2:30 p.m. (MT) at the Telus World of Science, 701-11 Street SW, Calgary.

Following the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics, will discuss recent progress in developing REOLYSIN(R) as a potential cancer therapeutic.

A live audio webcast of the presentation will begin at approximately 2:45 p.m. (MT) at:

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2632960 or on the company's website at www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible following the presentation at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
2. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
3. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
4. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
5. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
6. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
7. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
8. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
9. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
10. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
11. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a ... help treat hormonal and stress related hair loss. With patent-pending formulas for both ... key opinion leaders in the medical and salon channels nationwide. , Dermatologists, ...
(Date:5/3/2016)... , May 3, 2016 ... (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD ... (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, ... MarketsandMarkets, the market is expected to reach ... 7.63 Billion in 2015, growing at a ...
(Date:5/3/2016)... ... 03, 2016 , ... Morf Media Inc ., developer ... on mobile devices, today released a new interactive Food and Drug Administration ... course is essential for owners or operators of places of business that are ...
(Date:5/3/2016)... Boston, MA (PRWEB) , ... May 03, 2016 , ... ... ranked number 25 out of the state’s 76 fastest-growing private companies; a small percentage ... of Massachusetts, and ranked organizations on the percent change in revenue from 2012 to ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):